Amneal Pharmaceuticals receives FDA approval for Pyridostigmine Bromide Extended-Release Tablets 105 mg, a soman nerve agent protection for US & allied forces.

Amneal Pharmaceuticals has received FDA approval for its Pyridostigmine Bromide Extended-Release Tablets USP 105 mg. These once-daily tablets are designed to protect against soman nerve agent poisoning in adults and are intended for the U.S. Armed Services and allied forces. The product was developed with partial funding from the U.S. government and employs Amneal's GRANDE drug delivery technology.

October 21, 2024
4 Articles